克拉斯
癌症研究
免疫检查点
医学
封锁
细胞毒性T细胞
免疫疗法
免疫系统
免疫学
药理学
作者
Edurne Mugarza,Febe van Maldegem,Jesse Boumelha,Christopher Moore,Sareena Rana,Miriam Llorian,Philip East,Rachel Ambler,Panayiotis Anastasiou,Pablo Romero-Clavijo,Karishma Valand,Megan Cole,Míriam Molina‐Arcas,Julian Downward
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2022-07-20
卷期号:8 (29): eabm8780-eabm8780
被引量:148
标识
DOI:10.1126/sciadv.abm8780
摘要
Abstract Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harbouring KRAS G12C mutations, but drug resistance frequently develops. Due to the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect anti-tumour immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have characterised how KRAS G12C inhibition reverses immune suppression driven by oncogenic KRAS in a number of pre-clinical lung cancer models with varying levels of immunogenicity. Mechanistically, KRAS G12C inhibition upregulates interferon signaling via Myc inhibition, leading to reduced tumour infiltration by immunosuppressive cells, enhanced infiltration and activation of cytotoxic T cells, and increased antigen presentation. However, the combination of KRAS G12C inhibitors with immune checkpoint blockade only provides synergistic benefit in the most immunogenic tumour model. KRAS G12C inhibition fails to sensitize cold tumours to immunotherapy, with implications for the design of clinical trials combining KRAS G12C inhibitors with anti-PD1 drugs. One sentence summary KRAS inhibition mobilizes anti-tumour immunity in immunogenic lung cancer models through derepressing interferon signaling via repression of Myc.
科研通智能强力驱动
Strongly Powered by AbleSci AI